We found that either anti‐Pdl1 or Tug1‐siRNAs treatment partially inhibited tumor growth, and the combination had a synergistic effect on either tumor volumes (Figure 7H‐I) and tumor weights (Figure 7J), which confirmed that Tug1 could act as a potential therapeutic target to improve the therapeutic efficacy of Pdl1 checkpoint blockades. Here, TUG1 is linked to neoplasm.